Efficasy and safety of bevacizumab in combination with chemotherapy for treating the first recurrence of ovarian carcinoma : Phase 2 study
- Conditions
- recurrent ovarian caricinoma
- Registration Number
- JPRN-UMIN000016087
- Lead Sponsor
- Yokohama city univesity Obstetrics and Gynecology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 25
Not provided
(1)Patients with serious complications(such as uncontrolled diabetes) (2)Patients with below such severe heart disease congestive heart failure uncontrolled arrhythmia uncontrolled hypertension angina pectoris valvular heart disease (3)Patients with abdominal fistula of history, gastrointestinal perforation, intra-abdominal abscess,the symptoms of intestinal obstruction can not been able oral nutrition not-healing wounds, ulcers,fractions bleeding diathesis and significant coagulopathy Period of up to study treatment start from major surgery effective date is in the next 28 days,it is in the urine protein +2 or more at the time and registration (4) Patients with interstitial pneumonia or pulmonary fibrosis (5)patients with a history of severe drug hypersensitivity and drug allergy (6)Other, patients attending physician has determined that inadequate to safely carry out the present study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method Adverse event of bevacizumab response rate